



RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE
GROUP 1616
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q67010

Kazuya TAKENOUCHI, et al.

Appln. No.: 10/035,217

Group Art Unit: 1616

Confirmation No.: 4555

Examiner: Sabiha Naim Qazi

Filed: January 04, 2002

For: VITAMIN D3 DERIVATIVE AND TREATING AGENT FOR INFLAMMATORY
RESPIRATORY DISEASE USING SAME

RESPONSE UNDER 37 C.F.R. § 1.116

MAIL STOP AF

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated May 1, 2003, please consider the following
remarks.

REMARKS

Claims 46-54 are all the claims pending in the application.

Claims 46-54 are rejected under the judicially created doctrine of obviousness double
patenting as allegedly being unpatentable over claims 13-20 of U.S. Patent No. 6,531,460
(Application No. 089/830,167) and U.S. Patent No. 6,548,489 (Application No. 10/035,219).

The Examiner states that although the claims are not identical, they are not considered to
be patentably distinct since the method claims were joined with the compound claims.

RECEIVED
JUL 09 2003
TECH CENTER 1600
1616
7/21/03